FTSE 100: Index falls as earnings results weigh; pound below $1.33, Bodycote soars
In a challenging year for In8bio Inc, the biotechnology firm's stock has plummeted to a 52-week low, trading at just $0.14. This significant downturn reflects an 87% decrease from the previous year, with a market capitalization now at $11.6 million. According to InvestingPro analysis, the stock's RSI indicates oversold territory, suggesting potential overselling of the shares. Investors have witnessed a stark erosion in value, as the stock struggles amidst broader market trends and company-specific headwinds. With a current ratio of 4.08 and more cash than debt on its balance sheet, the company maintains strong liquidity despite its challenges. The 52-week low serves as a stark indicator of the hurdles In8bio Inc faces as it seeks to regain its footing in the competitive biotech landscape. InvestingPro analysis indicates the stock is currently undervalued, with 12 additional key insights available to subscribers.
In other recent news, IN8bio, Inc. has reported promising results from its Phase 1 trial of INB-100, a treatment for acute myeloid leukemia (AML). The trial results indicated a 100% relapse-free survival rate among patients, with a median follow-up of 20.1 months, significantly outperforming historical control groups. This positive data has led Jones Trading to upgrade IN8bio's stock rating from Hold to Buy, setting a new price target at $1.20. Meanwhile, H.C. Wainwright maintained its Buy rating but reduced the price target from $8.00 to $6.00 due to the dilutive effect of a recent capital raise.
Additionally, IN8bio announced the resignation of board member Travis Whitfill, effective May 9, 2025, noting that his departure is not due to any disagreements with the company. The company has not disclosed a successor or any changes to its governance structure following this announcement. These developments underscore IN8bio's ongoing clinical progress and strategic adjustments as it continues to advance its therapeutic platforms. The company's recent achievements and board changes are likely to be of interest to investors monitoring its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.